Weekly Research Analysts’ Ratings Changes for Alkermes (ALKS)

A number of firms have modified their ratings and price targets on shares of Alkermes (NASDAQ: ALKS) recently:

• 2/28/2026 – Alkermes was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/26/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright. They now have a $43.00 price target on the stock.
• 2/26/2026 – Alkermes had its price target raised by Wells Fargo & Company from $37.00 to $43.00. They now have an “overweight” rating on the stock.
• 2/26/2026 – Alkermes had its price target lowered by Royal Bank Of Canada from $47.00 to $45.00. They now have an “outperform” rating on the stock.
• 2/23/2026 – Alkermes is now covered by Wolfe Research. They set an “outperform” rating and a $45.00 price target on the stock.
• 2/23/2026 – Alkermes is now covered by Wolfe Research. They set an “outperform” rating and a $45.00 price target on the stock.
• 2/20/2026 – Alkermes had its price target raised by Bank of America Corporation from $33.00 to $34.00. They now have a “neutral” rating on the stock.
• 2/19/2026 – Alkermes was downgraded by Zacks Research from “strong-buy” to “hold”.
• 1/13/2026 – Alkermes was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Buying and Selling at Alkermes

In other news, SVP Christian Todd Nichols sold 6,000 shares of Alkermes stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the transaction, the senior vice president directly owned 109,769 shares in the company, valued at approximately $3,293,070. This trade represents a 5.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Joseph Gaffin sold 2,034 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $29.29, for a total value of $59,575.86. Following the completion of the transaction, the executive vice president directly owned 237,660 shares of the company’s stock, valued at approximately $6,961,061.40. The trade was a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 157,434 shares of company stock valued at $5,305,794. 4.40% of the stock is owned by corporate insiders.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.